Stanford University
Showing 121-130 of 515 Results
-
Maximilian Diehn, MD, PhD
Jack, Lulu, and Sam Willson Professor and Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMy laboratory focuses on two main areas: 1) cancer stem cell biology and 2) novel biomarkers for identifying the presence of malignant cells (diagnostic), predicting outcome (prognostic), and predicting response to therapy (predictive). Areas of study include cancers of the lung, breast, and gastrointestinal system. Clinically I specialize in the treatment of lung cancer and applications of stereotactic ablative radiotherapy and perform both prospective and retrospective clinical studies.
-
Frederick M. Dirbas, MD
Associate Professor of Surgery (General Surgery) and, by courtesy, of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsCurrently collaborating with Dr's Aaron Newman and Michael Clarke to study cancer stem cells associated with triple negative breast cancer. Advancing studies of FLASH radiotherapy in preclinical models for potential future use in humans. Investigating preclinical use of high dose gaseous nitric oxide in the treatment of solid tumors.
-
Vasu Divi, MD
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS)
BioDr. Vasu Divi is a distinguished expert in the field of head and neck cancer treatment, renowned for his dual roles as a cancer surgeon and reconstructive surgeon. With a specialized focus on high-risk and advanced skin cancers, oral cavity cancers, and osteoradionecrosis of the head and neck, Dr. Divi stands at the forefront of medical innovation. As a national authority in cutaneous squamous cell carcinoma of the head and neck, Dr. Divi spearheads Stanford's clinical trial program dedicated to this condition. His trial portfolio encompasses both neoadjuvant and adjuvant applications of immunotherapy, reflecting his commitment to advancing treatment methodologies. Actively engaged in research, Dr. Divi endeavors to define the optimal treatment approach for this disease, integrating immunotherapy to enhance patient outcomes.
-
Scott Dixon
Professor of Biology
Current Research and Scholarly InterestsMy lab is interested in the relationship between cell death and metabolism. Using techniques drawn from many disciplines my laboratory is investigating how perturbation of intracellular metabolic networks can result in novel forms of cell death, such as ferroptosis. We are interested in applying this knowledge to find new ways to treat diseases characterized by insufficient (e.g. cancer) or excessive (e.g. neurodegeneration) cell death.
-
Sarah S. Donaldson, MD
Catharine and Howard Avery Professor in the School of Medicine, Emerita
Current Research and Scholarly InterestsCombined Modality Treatment of Cancer
Late Effects of Treatment
Genetic Effects of Cancer
Rhabdomyosarcoma
Hodgkins Disease
Pediatric Radiation Oncolgy
Pediatric Oncolgy
Breast Cancer
Conformal Radiotherapy/IMRT
Radiotherapy for Benign Diseases -
Fei Dong
Associate Professor of Pathology
BioDr. Dong is the Director of Molecular Pathology at Stanford Health Care. The Molecular Pathology laboratory offers a broad menu of clinical diagnostic tests ranging from PCR to next generation sequencing. Dr. Dong's academic interests include the clinical implementation of laboratory developed tests, the development of novel informatics algorithms, and characterization of disease by molecular methods. Before arriving at Stanford, Dr. Dong was on faculty at Brigham and Women’s Hospital/Harvard Medical School for nine years, where he established a track record in education and mentorship and was the recipient of both the Anatomic Pathology and Clinical Pathology resident teaching awards. Dr. Dong has served on committees for the Association for Molecular Pathology, the Clinical and Laboratory Standards Institute, and the United States and Canadian Academy of Pathology. He serves on the editorial boards of multiple scientific journals and is an Associate Editor for the Journal of Molecular Diagnostics.
-
Asiri Ediriwickrema MD, PhD
Assistant Professor of Medicine (Hematology)
BioAsiri Ediriwickrema, MD, PhD, is an Assistant Professor of Medicine (Hematology) at the Stanford University School of Medicine. His clinical focus is on the diagnosis, evaluation, and management of patients with myelodysplastic neoplasms and clonal hematopoiesis.
Dr. Ediriwickrema earned his undergraduate degree in Engineering from the Massachusetts Institute of Technology, his MD (Cum Laude) from Yale University, and his PhD from Stanford University. He completed his residency in Internal Medicine and fellowship in Hematology at Stanford, where he also conducted his doctoral and postdoctoral research in the laboratory of Dr. Ravi Majeti. His research identified novel populations of multipotent progenitor cells in normal hematopoiesis and leukemia stem cells in acute myeloid leukemia (AML).
He currently leads a systems hematology laboratory that integrates advanced single-cell technologies, computational biology, and functional hematology to study both normal and malignant blood development. His research has been supported by numerous awards, including the NIH Ruth L. Kirschstein National Research Service Award (F32), the American Society of Hematology Scholar Award, and the Edward P. Evans Foundation Young Investigator Award. -
Bradley Efron
Max H. Stein Professor and Professor of Statistics and of Biomedical Data Science, Emeritus
Current Research and Scholarly InterestsResearch Interests:
BOOTSTRAP
BIOSTATISTICS
BAYESIAN STATISTICS
